Immunotherapeutics /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Donev, Rossen (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, MA : Academic Press, 2022.
Colección:Advances in protein chemistry and structural biology ; 129
Temas:
Immunotherapy.
Immunotherapy
Immunoth�erapie.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Immunotherapeutics
  • Copyright
  • Contents
  • Contributors
  • Chapter One: In silico tools and databases for designing cancer immunotherapy
  • 1. Introduction
  • 2. Cancer associated genomic data
  • 2.1. Genome profile repositories
  • 2.2. Mutation profile databases
  • 2.3. Cancer biomarker repositories
  • 3. Immunological database
  • 4. Analysis of genomic profiles
  • 5. Prediction of cancer biomarkers
  • 6. Identification of vaccine candidates
  • 6.1. B-cell epitope
  • 6.2. MHC binders
  • 6.3. T-cell epitope
  • 6.4. Cytokines inducing peptides
  • 6.5. Neoepitope for cancer
  • 7. Important pipelines
  • 7.1. HLA typing
  • 7.2. Neoantigen
  • 8. Cancer-specific immunotherapy
  • 9. Miscellaneous
  • 10. Discussion and conclusion
  • Acknowledgments
  • References
  • Chapter Two: Immunotherapeutic approaches for HPV-caused cervical cancer
  • 1. Introduction
  • 2. HPV
  • 2.1. Structure
  • 2.2. HPV types
  • 2.3. Viral life cycle and pathogenesis
  • 2.4. Immune response to HPV infection
  • 3. Vaccines
  • 4. HPV therapeutic vaccines
  • 4.1. Peptide-/protein-based vaccines
  • 4.2. Vector-based vaccines
  • 4.3. Nano-delivery systems
  • 4.4. DNA-based vaccines
  • 4.5. RNA-based vaccines
  • 4.6. Cell-based vaccines
  • 4.6.1. Dendritic cell-based vaccines
  • 4.6.2. Tumor-cell-based vaccines
  • 4.6.3. Adoptive T-cell therapy
  • 4.7. Therapeutic HPV vaccines in combination with therapeutic modalities
  • 4.7.1. Therapeutic HPV vaccines accompanied by immune checkpoint blockade
  • 4.7.2. Therapeutic HPV vaccines along with chemo-immunotherapy and radiotherapy
  • 4.7.3. Therapeutic HPV vaccines in combination with other treatment modalities
  • 5. Conclusion
  • Funding
  • Conflicts of interest
  • References
  • Chapter Three: Natural killer cell-based strategies for immunotherapy of cancer
  • 1. Natural killer cells origin and functions
  • 2. NK cell recognition in health and disease
  • 2.1. NK cell receptor families
  • 2.1.1. C-type lectin-like receptors
  • 2.1.2. Killer immunoglobulin-like receptors
  • 2.1.3. Natural cytotoxicity receptors
  • 3. NK cells as a tool of cancer immunotherapy
  • 3.1. Cancer immunosurveillance
  • 3.2. Mechanisms of tumor escape from NK cell immunosurveillance
  • 4. NK cell-based immunotherapeutics
  • 4.1. Activated NK cell-based therapeutics
  • 4.2. Recombinant protein-based NK cell therapeutics
  • 4.3. Gene-modified NK cell-based therapeutics
  • 5. Concluding remarks
  • Acknowledgments
  • References
  • Chapter Four: Noncoding RNAs as novel immunotherapeutic tools against cancer
  • 1. Introduction
  • 2. Immunotherapy in human diseases
  • 3. Immunotherapy in cancer
  • 4. Noncoding RNAs in cancer
  • 4.1. Reprogramming of macrophage differentiation & function by ncRNAs
  • 4.2. Modulation of natural killer cell mediated cytotoxicity by ncRNAs
  • 4.3. Regulation of neutrophil plasticity & activity by ncRNAs

Ejemplares similares